Clinical Trials
Metastatic Prostate Cancer That No longer Responds to Androgen Deprivation Treatment (mCRPC)

This Information is provided to help patients identify clinical trials for educational purposes and not to recruit patients for any specific trials. Patients should consult with their personal doctor and the trial sponsors for additional information on trials of interest.

Study of Ipilimumab following completion of sipuleucel-T (SipT) treatment in Prostate Cancer Patients

Number: NCT01804465
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco|M.D. Anderson Cancer Center|Bristol-Myers Squibb|Dendreon
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Immunotherapy plus Radiation to improve Patient treatment outcomes

Number: NCT01818986
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Texas Southwestern Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Gene Therapy + Valacyclovir in Combination With Brachytherapy for Recurrent Prostate Cancer

Number: NCT01913106
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The Methodist Hospital System
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to compare prostate cancers treated with hormone therapy versus prostate cancers treated with hormone therapy plus drugs that directly target cancer cells

Number: NCT01990196
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Enzalutamide and Mifepristone in Treating Patients With Prostate Cancer

Number: NCT02012296
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Chicago|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of a molecular inhibitor in patients with genetic mutations

Number: NCT02203513
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Abiraterone With or Without Cabazitaxel in Treatment of mCRPC

Number: NCT02218606
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center|Sanofi|Thomas Jefferson University|Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Immunotherapy and Radiation in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Number: NCT02463799
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study of Ribociclib in Combination With Docetaxel Plus Prednisone in mCRPC

Number: NCT02494921
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Number: NCT02499835
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide and Cabazitaxel in Treating Patients With mCRPC

Number: NCT02522715
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OHSU Knight Cancer Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With and Without Ribociclib for mCRPC patients who have not received chemotherapy

Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study of Sirolimus, Docetaxel, and Carboplatin in Treating Patients With mCRPC

Number: NCT02565901
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Nivolumab and Ipilimumab in Treating Patients With mCRPC

Number: NCT02601014
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of a Molecular Inhibitor in Prostate Cancer Patients

Number: NCT02649790
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Karyopharm Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Docetaxel and PROSTVAC for mCRPC

Number: NCT02649855
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study to find out if the combination of apalutamide, abiraterone acetate, and prednisone can be given with either ipilimumab or cabazitaxel plus carboplatin to control metastatic CRPC

Number: NCT02703623
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Bristol-Myers Squibb|Janssen, LP|Sanofi
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of a molecular inhibitor in Combination With Enzalutamide in Patients With mCRPC

Number: NCT02711956
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Zenith Epigenetics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With mCRPC

Number: NCT02807805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Chong-xian Pan|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Proxalutamide in Subjects With mCRPC

Number: NCT02826772
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study of the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients

Number: NCT02844582
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, Davis|Sanofi
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study of how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery

Number: NCT02849990
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Number: NCT02854436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02881242
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Olaparib With or Without Cediranib in Treating Patients With mCRPC

Number: NCT02893917
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Number: NCT02903160
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Icahn School of Medicine at Mount Sinai|Sanofi|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, Davis|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Rucaparib in Patients With mCRPC and Genetic Mutations

Number: NCT02952534
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Clovis Oncology, Inc.|Foundation Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Number: NCT02975934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Clovis Oncology, Inc.|Foundation Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Number: NCT02985021
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seattle Institute for Biomedical and Clinical Research|Prostate Cancer Foundation|VA Puget Sound Health Care System
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Olaparib Versus Enzalutamide or Abiraterone Acetate in Men With mCRPC (PROfound Study)

Number: NCT02987543
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): AstraZeneca|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TRC253, an Androgen Receptor Antagonist in mCRPC Patients

Number: NCT02987829
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tracon Pharmaceuticals Inc.|Janssen Pharmaceutica N.V., Belgium
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab in Combination With Intratumoral SD-101 Therapy

Number: NCT03007732
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Lawrence Fong|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With mCRPC With DNA Repair Defects

Number: NCT03012321
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|AstraZeneca|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Treatment with Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer

Number: NCT03069937
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|Ferring Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With mCRPC

Number: NCT03072238
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hoffmann-La Roche
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

Number: NCT03093272
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Janssen Pharmaceutica
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Number: NCT03093428
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With mCRPC

Number: NCT03098836
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Daniel George, MD|Janssen Scientific Affairs, LLC|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Talazoparib in Men With DNA Repair Defects and mCRPC

Number: NCT03148795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Pfizer|Medivation, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Number: NCT03170960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Using Imaging for Detection of mCRPC

Number: NCT03173924
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Tremelimumab + Durvalumab Chemotherapy Naive CRPC

Number: NCT03204812
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|MedImmune LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Number: NCT03246347
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Earle Burgess|Astellas Pharma Inc|Medivation, Inc.|Carolinas Healthcare System
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab in mCRPC With or Without DNA Damage Repair Defects

Number: NCT03248570
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Number: NCT03263650
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|AstraZeneca|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Number: NCT03298087
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Number: NCT03304418
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Number: NCT03330405
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in mCRPC

Number: NCT03338790
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb|Clovis Oncology|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients

Number: NCT03360721
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Scientific Affairs, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Number: NCT03367819
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sanofi
Sponsor Trial Information
Trial Location(s) and Contact(s)
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC With Deoxyribonucleic Acid (DNA) Damage Repair Deficiencies (DDR)

Number: NCT03395197
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Number: NCT03409458
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Phosplatin Therapeutics|Pfizer|EMD Serono
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

Number: NCT03413995
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With mCRPC

Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Trovagene, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Number: NCT03418324
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel

Number: NCT03419234
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Niraparib Combination Therapies for the Treatment of mCRPC

Number: NCT03431350
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

Number: NCT03456804
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Navarixin in Combination With Pembrolizumab in Adults With Selected Advanced/Metastatic Solid Tumors

Number: NCT03473925
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03480646
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Constellation Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)

Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Number: NCT03511664
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Endocyte
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer

Number: NCT03516812
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
COMbination of Bipolar Androgen Therapy and Nivolumab

Number: NCT03554317
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Number: NCT03556904
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Michigan Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Number: NCT03570619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Michigan Cancer Center|Memorial Sloan Kettering Cancer Center|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Number: NCT03678025
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Southwest Oncology Group|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)








PHEN,Inc. © 2018 All rights reserved